TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15196143

Group type: EXPERIMENTAL
Intervention: Stellate ganglion near-infrared irradiation (SGR) once weekly for 4 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: SGR
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 37
Study: 12095056

Group type: EXPERIMENTAL
Intervention: Basiliximab (20mg day 0‐day 4) plus early cyclosporine from day 0
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thymoglobulin plus delayed cyclosporine
Number of subjects: 100
Study: 9794094

Group type: EXPERIMENTAL
Intervention: 17 mmol/d Mg orotate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study: 8637449

Group type: EXPERIMENTAL
Intervention: Thyrotropin (TSH)‐releasing hormone (TRH)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone (GnRH)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ovine corticotropin (ACTH)‐releasing hormone (oCRH)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Human growth hormone‐(GH)‐releasing hormone (hGHRH)
Number of subjects: 35

Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 35
Study: 2206032

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 102
Study: 7297143

Group type: EXPERIMENTAL
Intervention: 0.4 mg pindolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled isoproterenol
Number of subjects: 24
Study: 31631813

Group type: EXPERIMENTAL
Intervention: CaringGuidance™ plus usual care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 28666425

Group type: EXPERIMENTAL
Intervention: Task shared psycho-social counselling intervention
Number of subjects: 6
Study: 24943996

Group type: EXPERIMENTAL
Intervention: Booster session (n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Program without booster session (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 60
Study: 24993765

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Memantine (responders)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22170972

Group type: COMPARATOR
Intervention: Standard tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deviant tones
Number of subjects: 0
Study: 20200309

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17945435

Group type: EXPERIMENTAL
Intervention: Ghrelin (50 microg boluses at 22:00, 23:00, 00:00, and 01:00 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 10
Study: 16004250

Group type: EXPERIMENTAL
Intervention: Calcium carbonate/perlite toothpaste
Number of subjects: 152

Group type: COMPARATOR
Intervention: Silica control toothpaste
Number of subjects: 152
Study: 12011527

Group type: EXPERIMENTAL
Intervention: Povidone iodine suppositories
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lactobacilli capsules
Number of subjects: 70
Study: 10465068

Group type: EXPERIMENTAL
Intervention: rgp160 IIIB vaccine
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 7494809

Group type: EXPERIMENTAL
Intervention: Deflazacort (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylprednisolone (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone (25 mg)
Number of subjects: 0
Study: 2185791

Group type: EXPERIMENTAL
Intervention: Nicardipine (2.5 mg/h, increasing in steps of 2.5 mg/h at 2 h intervals, maximum rate 7.5 mg/h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30
Study: 677433

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Levallorphan
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31731005

Group type: EXPERIMENTAL
Intervention: Tropifexor (TXR) 140 μg once daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg once daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tropifexor (TXR) 140 μg once daily + Cenicriviroc (CVC) 150 mg once daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tropifexor (TXR) 90 μg once daily + Cenicriviroc (CVC) 150 mg once daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combination therapy (TXR + CVC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Monotherapies (TXR or CVC)
Number of subjects: 200
Study: 31093755

Group type: EXPERIMENTAL
Intervention: 1 g metformin every 12 hours for five consecutive days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual management only
Number of subjects: 30
Study: 27879195

Group type: EXPERIMENTAL
Intervention: Test formulation of baclofen 10 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference formulation of baclofen 10 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of test to reference formulation
Number of subjects: 22
Study: 26032114

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 3759

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3759
Study: 23524695

Group type: EXPERIMENTAL
Intervention: Intracortical approach
Number of subjects: 73

Group type: COMPARATOR
Intervention: Medial approach
Number of subjects: 73
Study: 21652026

Group type: EXPERIMENTAL
Intervention: Photographic vitreous haze grading technique using a 9-step logarithmic scale
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Photographic vitreous haze grading technique
Number of subjects: 142
Study: 18785846

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (9.7 J/cm(2), 830 nm) for 10 min
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 45
Study: 16626571

Group type: EXPERIMENTAL
Intervention: Intracoronary PBSCs transplantation following G-CSF mobilization (300-600 microg/day for 5 days)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intracoronary PBSCs transplantation following G-CSF mobilization
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard therapy (standard drug therapy and PCI)
Number of subjects: 70
Study: 14709757

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11239180

Group type: COMPARATOR
Intervention: Magnetization Transfer Imaging (MTI)
Number of subjects: 33
Study: 9632036

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9753961

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg 3 min prior to propofol
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg added to 200 mg propofol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Propofol 2 mg.kg‐1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg 3 min prior to propofol mixed with lidocaine 40 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Injection via the forearm vein
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Groups receiving fentanyl
Number of subjects: 160
Study: 2497096

Group type: EXPERIMENTAL
Intervention: Oxaprozin 600 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg t.i.d.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 130153

Group type: EXPERIMENTAL
Intervention: 2% carbonated lignocaine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine HCl
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: 2% carbonated lignocaine with adrenaline
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine HCl with adrenaline
Number of subjects: 335

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Plain lignocaine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Other groups
Number of subjects: 335
Study: 30585904

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 27

Group type: COMPARATOR
Intervention: Daily caffeine intake
Number of subjects: 27
Study: 29388827

Group type: EXPERIMENTAL
Intervention: Couples-oriented education and support (CES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient education and support (PES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 30
Study: 28861902

Group type: EXPERIMENTAL
Intervention: Clinician-led Body Project groups
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Peer-led Body Project groups
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Internet-based version of the Body Project (eBodyProject)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Educational video control condition
Number of subjects: 680
Study: 26742334

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy by group 1 SRNAs
Number of subjects: 9

Group type: COMPARATOR
Intervention: Direct laryngoscopy after observing video laryngoscopy by group 2 SRNAs
Number of subjects: 9
Study: 23937756

Group type: EXPERIMENTAL
Intervention: Minimally invasive unilateral pedicle screw fixation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Classic bilateral pedicle screw fixation
Number of subjects: 85
Study: 21285389

Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: AF
Number of subjects: 178

Group type: COMPARATOR
Intervention: IGlar
Number of subjects: 178
Study: 19253130

Group type: EXPERIMENTAL
Intervention: AMP-RT (in-home asthma management program provided by respiratory therapists)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: AMP-RN (in-home asthma management program provided by nurses)
Number of subjects: 159

Group type: COMPARATOR
Intervention: UC (usual care provided in physician offices or clinics)
Number of subjects: 159
Study: 16884070

Group type: EXPERIMENTAL
Intervention: Cefmenoxime hydrochloride (CMX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 0
Study: 15256687

Group type: EXPERIMENTAL
Intervention: Mixture of whey protein (17.5 g), amino acids (4.9 g), and carbohydrates (77.4 g) (PAAC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isoenergetic carbohydrates (100 g) (CON)
Number of subjects: 8
Study: 11282765

Group type: EXPERIMENTAL
Intervention: Therapeutic nasal continuous positive airway pressure (CPAP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Subtherapeutic nasal continuous positive airway pressure (CPAP) (0-1 cm H(2)O)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ineffective nasal continuous positive airway pressure (CPAP)
Number of subjects: 46
Study: 9137476

Group type: EXPERIMENTAL
Intervention: D‐galactose (1.9 g/kg BW and day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: D‐glucose‐containing electrolyte infusions
Number of subjects: 76
Study: 7964541

Group type: EXPERIMENTAL
Intervention: Alpha-galactosidase solution (8 drops)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (8 drops)
Number of subjects: 19
Study: 3058656

Group type: EXPERIMENTAL
Intervention: Prostatic bed irradiation only (6500 cGy at 180‐200 cGy per treatment)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Pelvic node irradiation to 4500 cGy with a boost of 2000 cGy to the prostatic bed (total dose 6500 cGy)
Number of subjects: 445
Study: 31022069

Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 30

Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 30
Study: 28254694

Group type: EXPERIMENTAL
Intervention: Training (T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Energy-reduced diet (D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Training and increased diet (T-iD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sedentary lifestyle and unchanged diet (C)
Number of subjects: 60
Study: 25611899

Group type: EXPERIMENTAL
Intervention: Nonpegylated doxorubicin citrate (60 mg/m) and carboplatin (AUC 5) every 3 weeks for 6 to 9 cycles
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nonpegylated doxorubicin citrate and carboplatin
Number of subjects: 39
Study: 23994252

Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Number of subjects: 81
Study: 21516059

Group type: COMPARATOR
Intervention: Levothyroxine sodium soft capsule formulation (Tirosint)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50-, 100-, and 150-μg test capsules strengths dosed at 600 μg
Number of subjects: 90

Group type: COMPARATOR
Intervention: New capsule formulation following the new potency guideline (±5%)
Number of subjects: 90
Study: 18377142

Group type: EXPERIMENTAL
Intervention: Telephone psychotherapy for depression
Number of subjects: 127
Study: 16601647

Group type: EXPERIMENTAL
Intervention: Paroxetine (10-50 mg/day)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 12594688

Group type: EXPERIMENTAL
Intervention: Angio‐Seal
Number of subjects: 612

Group type: COMPARATOR
Intervention: Compression methods
Number of subjects: 612
Study: 10733124

Group type: EXPERIMENTAL
Intervention: OK-432 and fibrinogen plus 5'‐deoxy‐5‐fluorouridine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5'‐deoxy‐5‐fluorouridine only
Number of subjects: 20
Study: 8738591

Group type: EXPERIMENTAL
Intervention: Preoperative platelet count (PlC) levels
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Preoperative platelet count (PlC) quartiles
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Preoperative platelet count (PlC) levels adjusted for age, sex, type of surgery and type of prophylaxis
Number of subjects: 438
Study: 1305891

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐n3 (Alferon N Injection)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 2867653

Group type: COMPARATOR
Intervention: etintidine 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: etintidine 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: cimetidine 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 0
Study: 29779912

Group type: EXPERIMENTAL
Intervention: Procedural analgesia or sedation during painful procedures
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Skin-breaking procedures
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Mechanically ventilated patients
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Overall number of painful and stressful procedures
Number of subjects: 229
Study: 30020219

Group type: EXPERIMENTAL
Intervention: 12-week exercise program
Number of subjects: 43

Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 43
Study: 27209237

Group type: EXPERIMENTAL
Intervention: Pelvic intraoperative neuromonitoring (pIONM)
Number of subjects: 188

Group type: COMPARATOR
Intervention: No pelvic intraoperative neuromonitoring (pIONM)
Number of subjects: 188
Study: 25209306

Group type: EXPERIMENTAL
Intervention: Methadone initiation in primary care
Number of subjects: 195

Group type: COMPARATOR
Intervention: Methadone initiation in specialized centers
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Living in a couple with a non-drug user
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Living in a couple with a drug user
Number of subjects: 195
Study: 21989542

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 752

Group type: COMPARATOR
Intervention: Etanercept (both doses)
Number of subjects: 752
Study: 20979784

Group type: EXPERIMENTAL
Intervention: rhPTH (1‐34) 20 µg daily
Number of subjects: 205

Group type: COMPARATOR
Intervention: elcatonin 20 U weekly
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: rhPTH (1‐34)
Number of subjects: 205
Study: 18729145

Group type: EXPERIMENTAL
Intervention: 2-week exercise intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2-week exercise plus cognitive restructuring intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 60
Study: 16093464

Group type: EXPERIMENTAL
Intervention: Alendronate after parathyroid hormone (1-84) therapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo after parathyroid hormone (1-84) therapy
Number of subjects: 119
Study: 12501881

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg administered on the last day of the OC regimen
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Norethindrone 1 mg/ethinyl estradiol 0.035 mg (NE/EE)
Number of subjects: 26
Study: 10626585

Group type: EXPERIMENTAL
Intervention: Neonatal screening using transient evoked oto-acoustic emissions (TEOAE) test followed by automated auditory brainstem response (AABR) test for infants who failed TEOAE.
Number of subjects: 53781

Group type: EXPERIMENTAL
Intervention: Neonatal screening periods
Number of subjects: 53781

Group type: EXPERIMENTAL
Intervention: Neonatal screening
Number of subjects: 53781

Group type: COMPARATOR
Intervention: Health Visitor Distraction Test (HVDT) screening
Number of subjects: 53781
Study: 7536530

Group type: EXPERIMENTAL
Intervention: Urethral temperature between 42 and 43 degrees C
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Urethral temperature between 43.1 and 45 degrees C
Number of subjects: 91
Study: 1645384

Group type: EXPERIMENTAL
Intervention: SDZ 89‐104, 2 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SDZ 89‐109, 2 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SDZ 89‐104, 0.5 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SDZ 89‐109, 0.5 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High serum levels (2 mg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Serum half-lives
Number of subjects: 13
Study: 7098411

Group type: EXPERIMENTAL
Intervention: Kavinton
Number of subjects: 8

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31864339

Group type: EXPERIMENTAL
Intervention: Behavioural intervention program including self-management education and measurement of weight, waist circumference, and blood pressure for 3 months.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Leaflet on the importance of controlling hypertension.
Number of subjects: 92
Study: 28738008

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (15 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25941765

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300 mg per day for 20 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo supplementation (300 mg per day for 20 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (CoQ10 and placebo)
Number of subjects: 18
Study: 24885672

Group type: EXPERIMENTAL
Intervention: Conventional Western medicine (Salbutamol, Formoterol, Salmeterol/fluticasone)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatments (Bufei granule, Bu‐Fei Jian‐Pi granule, Bu‐Fei Yi‐Shen granule, Yi‐Qi Zi‐Shen granule)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Combination of conventional Western medicine and TCM treatments
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 360
Study: 22131604

Group type: EXPERIMENTAL
Intervention: CBT plus BLT
Number of subjects: 49

Group type: COMPARATOR
Intervention: WL
Number of subjects: 49
Study: 20165628

Group type: EXPERIMENTAL
Intervention: Physical exercise (brisk walking for 50-60 minutes, four days/week)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Salt intake reduction (to at least half of previous intake)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Yoga (30-45 minutes/day on at least five days/week)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 113
Study: 17445432

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (300 mg and 600 mg)
Number of subjects: 60
Study: 14709457

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 10 mg.kg(‐1) bolus before surgery plus a 1 mg.kg(‐1).hr(‐1) infusion until wound closure (Group TA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 40
Study: 11470689

Group type: EXPERIMENTAL
Intervention: High Dk RGP lenses
Number of subjects: 201

Group type: COMPARATOR
Intervention: Medium Dk RGP lenses
Number of subjects: 201
Study: 9737091

Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg/d for 6 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: indomethacin 25 mg tid for 2 days and 25 mg on the 3rd day
Number of subjects: 15

Group type: COMPARATOR
Intervention: no NSAID (control)
Number of subjects: 15
Study: 7995320

Group type: EXPERIMENTAL
Intervention: Nonfiltered 0 mg nicotine cigarette
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low (0.27 mg) nicotine cigarette
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High (2.16 mg) nicotine cigarette
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonsmokers (control group)
Number of subjects: 20
Study: 2843029

Group type: EXPERIMENTAL
Intervention: Oat and bean products as dietary supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-carbohydrate, high-fiber diets
Number of subjects: 0
Study: 29966645

Group type: EXPERIMENTAL
Intervention: Interactive group treatment (13 weekly sessions, 1.5 hours each) with structured and facilitated group interactions
Number of subjects: 179

Group type: COMPARATOR
Intervention: Noninteractive treatment (13 traditional classroom sessions with brief supplemental individual sessions)
Number of subjects: 179
Study: 26867200

Group type: EXPERIMENTAL
Intervention: DHA supplementation alone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: DHA as part of a multinutrient supplement (including Gingko biloba, phosphatidylserine, vitamins B₉ and B₁₂)
Number of subjects: 86